These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1661121)

  • 1. Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients. A comparison with standard heparin.
    Nurmohamed MT; ten Cate J; Stevens P; Hoek JA; Lins RL; ten Cate JW
    ASAIO Trans; 1991; 37(3):M459-61. PubMed ID: 1661121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
    Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F
    Nephron; 2002; 92(3):589-600. PubMed ID: 12372942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of low molecular weight heparin and standard heparin in hemodialysis.
    Bambauer R; Rücker S; Weber U; Köhler M
    ASAIO Trans; 1990; 36(3):M646-9. PubMed ID: 2174689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anticoagulation of the extracorporeal circuit in chronic hemodialysis].
    Ryckelynck JP; Chouraqui D; Lobbedez T
    Nephrologie; 1998; 19(4):223-5. PubMed ID: 9675763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of heparins in end-stage renal disease.
    Sonawane S; Kasbekar N; Berns JS
    Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
    Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
    Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
    Frank RD; Müller U; Lanzmich R; Groeger C; Floege J
    Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis.
    Al-Saran KA; Sabry A; Taha M; Ghafour MA; Al Fawzan F
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):43-9. PubMed ID: 20061691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with a new antithrombotic (dermatan sulfate) in chronic hemodialysis patients.
    Nurmohamed MT; Knipscheer HC; Stevens P; Krediet RT; Roggekamp MC; Berckmans RJ; ten Cate JW
    Clin Nephrol; 1993 Mar; 39(3):166-71. PubMed ID: 8462205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A low molecular weight heparin in hemodialysis.
    Maurin N; Kierdorf H
    Klin Wochenschr; 1988 Mar; 66(6):246-9. PubMed ID: 2835544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin.
    Anastassiades E; Lane DA; Ireland H; Flynn A; Curtis JR
    Clin Nephrol; 1989 Dec; 32(6):290-6. PubMed ID: 2558829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of enoxaparine for anticoagulation in extracorporeal circulation in hemodialysis at high risk for hemorrhage].
    Dechelette E; Pouzol P; Jurkovitz C; Kuentz F; Polack B; Cuzin E; Woler M
    J Mal Vasc; 1987; 12 Suppl B():105-7. PubMed ID: 2834479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Appropriate dosage of unfraction heparin and low molecular weight heparin in hemodialysis patients].
    Xiao Q; Sun XF; Zhang D; Ma ZF; Wu MG; Wang H; Chen XM
    Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(3):187-91. PubMed ID: 20356555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.
    Borentain M; Montalescot G; Bouzamondo A; Choussat R; Hulot JS; Lechat P
    Catheter Cardiovasc Interv; 2005 Jun; 65(2):212-21. PubMed ID: 15900551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failure.
    Lane DA; Ireland H; Tew CJ; Flynn A; Curtis JR
    Acta Chir Scand Suppl; 1988; 543():101-4. PubMed ID: 2847457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cross-over study of a new low molecular weight heparin (Logiparin) in hemodialysis.
    Koutsikos D; Fourtounas C; Kapetanaki A; Dalamanga A; Tzanatos H; Agroyannis B; Kopelias I; Bosiolis B; Rammos G; Bovoleti O; Sallum G; Darema M
    Int J Artif Organs; 1996 Aug; 19(8):467-71. PubMed ID: 8841845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials.
    Lim W; Cook DJ; Crowther MA
    J Am Soc Nephrol; 2004 Dec; 15(12):3192-206. PubMed ID: 15579523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low molecular weight heparin in diabetic and nondiabetic hypercholesterolemic patients receiving long-term hemodialysis.
    Leu JG; Liou HH; Wu SC; Yang WC; Huang TP; Wu SC
    J Formos Med Assoc; 1998 Jan; 97(1):49-54. PubMed ID: 9481065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.